Cohance Lifesciences Limited — Investor Meet, 01-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Cohance Lifesciences held a call on leadership changes. MD Dr. Prasada Raju resigned for personal reasons, with transition support. To accelerate its $1 billion vision by 2030, the company restructured. Three business verticals (Pharma CDMO, API+, Specialty Chemicals) now have dedicated CEOs reporting to Executive Chairman Vivek Sharma. A new Platform COO is joining, and CFO Himanshu Agarwal joined the board.

Operational wins include four major CDMO order completions and a confirmed Phase 3 order from a key Japanese client. The Oligonucleotide unit is on track for Q4 commissioning. Management acknowledged some senior-level churn but highlighted new talent and an aggressive M&A pursuit for niche tech, signaling a confident push for stability and faster execution.